open access

Vol 10, No 1 (2005)
Published online: 2005-01-01
Submitted: 2004-03-31
Get Citation

Different schemes of B-cell chronic lymphocytic leukaemia (B-CLL) treatment in the population affected by the Chernobyl accident

Oksana M. Polyshchuk, Iryna S. Dyagil, Viktor I. Klymenko, Dimitry A. Bazyka, Iryna A. Kryachok
DOI: 10.1016/S1507-1367(05)71082-8
·
Rep Pract Oncol Radiother 2005;10(1):47-50.

open access

Vol 10, No 1 (2005)
Published online: 2005-01-01
Submitted: 2004-03-31

Abstract

Background

Remarkable advance in the knowledge of the biology and treatment of chronic lymphocytic leukaemia (CLL) has been noted in recent years. CLL resembles several heterogeneous diseases with variable morphological features. New agents with antileukemic activity have been introduced recently for CLL patients, which improved the treatment results. Fludarabin has shown its efficacy in CLL both as a treatment of choice and in combination with conventional cytostatic agents. Clinical and haematological features of B-CLL in persons affected by the Chernobyl accident in the last period are presented.

Aim

The aim of this study was the comparison of two chemotherapy different schemes for B-CLL treatment.

Materials/Methods

The study was based on 32 patients with diagnosis of B-CLL who were treated at the Hematology Department. Depending upon the protocol all patients were classified in two subgroups: I – fludarabine monotherapy treatment, II – fludarabine with combination with other chemotherapy preparations.

Results

Of the treatment are analyzed for 16 patients after different chemotherapy regimens. A combined fludarabine and cyclophosphamide regimen has been shown to improve long-term complete and partial remission in the majority of patients as compared with a more conservative approach.

Abstract

Background

Remarkable advance in the knowledge of the biology and treatment of chronic lymphocytic leukaemia (CLL) has been noted in recent years. CLL resembles several heterogeneous diseases with variable morphological features. New agents with antileukemic activity have been introduced recently for CLL patients, which improved the treatment results. Fludarabin has shown its efficacy in CLL both as a treatment of choice and in combination with conventional cytostatic agents. Clinical and haematological features of B-CLL in persons affected by the Chernobyl accident in the last period are presented.

Aim

The aim of this study was the comparison of two chemotherapy different schemes for B-CLL treatment.

Materials/Methods

The study was based on 32 patients with diagnosis of B-CLL who were treated at the Hematology Department. Depending upon the protocol all patients were classified in two subgroups: I – fludarabine monotherapy treatment, II – fludarabine with combination with other chemotherapy preparations.

Results

Of the treatment are analyzed for 16 patients after different chemotherapy regimens. A combined fludarabine and cyclophosphamide regimen has been shown to improve long-term complete and partial remission in the majority of patients as compared with a more conservative approach.

Get Citation

Keywords

chronic lymphocytic leukaemia; Fludarabine; immunophenotype; treatment

About this article
Title

Different schemes of B-cell chronic lymphocytic leukaemia (B-CLL) treatment in the population affected by the Chernobyl accident

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 10, No 1 (2005)

Pages

47-50

Published online

2005-01-01

DOI

10.1016/S1507-1367(05)71082-8

Bibliographic record

Rep Pract Oncol Radiother 2005;10(1):47-50.

Keywords

chronic lymphocytic leukaemia
Fludarabine
immunophenotype
treatment

Authors

Oksana M. Polyshchuk
Iryna S. Dyagil
Viktor I. Klymenko
Dimitry A. Bazyka
Iryna A. Kryachok

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl